Project Grant R43TR005112
Award Date
6/1/24
Completion Date
5/31/25
Dollars Obligated
$295K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
San Mateo, CA 94401, USA
Similar Awards
The federal Project Grant award of $350,000 was provided by the National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, to Vivosphere LLC in Auburn, AL. The funding will support the development of "Vivospheres", which are tissue-engineered spheroidal models for high-throughput screening. The project aims to establish Vivospheres as a more consistent and flexible 3D cell culture system compared to traditional self-aggregation methods, enabling...
This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...
This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $349,171 to Cellchorus Inc. to develop an integrated computer vision system called LF-TIMING (Label-Free TIMING). The goal is to enable large-scale, label-free profiling of cell-cell interactions, particularly between immune cells and tumor cells. The LF-TIMING system will leverage deep neural networks to accurately analyze phase-contrast video recordings,...
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
This Project Grant awarded by the National Institute of General Medical Sciences (NIGMS), under CFDA Program 93.859 Biomedical Research and Research Training, aims to advance the commercialization of an innovative automated cell culturing system. The $295,038 award to Altvivo, Inc. will enable the development of capabilities that overcome challenges in maintaining heterogeneous microenvironments and enable non-disruptive real-time analysis of cell cultures, without the need for sacrificial...
The Project Grant award under the National Center for Advancing Translational Sciences (NCATS) CFDA 93.350 program aims to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system that can rapidly and efficiently isolate extracellular vesicles (EVs) from various bodily fluids, including blood plasma, serum, urine, and saliva. The $1,077,369 award to Captis Diagnostics Inc., a small disadvantaged business, will support the optimization and validation of the LNP prototype as a...
This $400,000 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and evaluation of advanced CAR-T cell therapies for renal cell carcinoma (RCC). The awardee, Cellinfinity Bio Inc., is using novel CRISPR screening approaches to identify key genetic modifications that enhance CAR-T cell efficacy against RCC tumors. The proposed work includes assessing the combination of PRDM1 exon 3 knockout and CTLA-4 cytoplasmic tail fusion...